Amicus Therapeutics — 40th Annual J.P. Morgan Healthcare Conference 2022
29 slides from Amicus Therapeutics's conference presentation, Jan 10, 2022

Slide 1: At the Forefront of Therapies for Rare Diseases
40th Annual J.P. Morgan Healthcare Conference January 12, 2022 At the Forefront of Therapies for Rare Diseases

Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and

Slide 3: Our Passion is for Patients: Mission and Vision
3 Amicus Definition: \əˈmēkəs (noun) Latin Friend Our Passion is for Patients Our Mission: We seek to deliver the highest quality therapies for people living with rare diseases Our Vision: Be a leader in rare disease drug development and commercialization leveraging our expertise in bringing life-ch

Slide 4: A Rare Company
4 A Rare Company Leading, Patient Dedicated, Rare Disease Biotechnology Company with Sustained Double-Digit Revenue Growth, a Global Commercial Infrastructure, and Late-stage Development Capabilities Gene Therapy PLATFORM Protein Engineering & Glycobiology $557M Cash as of 9/30/21 AT-GAA a Two-Compo

Slide 5: 2021 Strategic Priorities Accomplished
2021 Strategic Priorities Accomplished: Setting the Stage for a Successful 2022 1 2 3 4 5 Achieve double-digit Galafold growth and revenue of $300M to $315M Report data from the AT-GAA Phase 3 PROPEL study and complete BLA and MAA filings for regulatory approvals Advance clinical studies, regulatory

Slide 6: 2022 Strategic Priorities to Drive Value
2022 Strategic Priorities to Drive Value 1 2 3 4 5 Continued double-digit Galafold growth (15-20%) with revenue of $350M to $365M Secure FDA approval and positive CHMP opinion for AT-GAA Initiate successful, rapid launch in U.S. for AT-GAA Advance best-in-class next-generation genetic medicines and

Slide 7: Amicus Pipeline
7 INDICATION DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL FABRY FRANCHISE Galafold®(migalastat) Fabry Gene Therapy POMPE FRANCHISE AT-GAA (cipaglucosidase alfa + miglustat) Pompe Gene Therapy NEXT- GENERATION RESEARCH PROGRAMS Multiple programs* Amicus Pipeline Streamlined Rare Dise

Slide 8: Positioned for Significant Value Growth
8 Positioned for Significant Value Growth Focused on Execution and Driving Sustainable Double-Digit Revenue Growth on Path to Profitability Continue to bring Galafold to as many patients as possible, sustain double digit revenue growth Successful launch of AT-GAA for people living with Pompe disease

Slide 9: Galafold (migalastat) Continued Growth
9 Galafold® (migalastat) Continued Growth... … building a leadership position in the treatment of Fabry disease

Slide 10: Fabry Disease Overview
10 Fabry Disease Overview .. Deficiency of α-Gal A enzyme leading to GL-3 accumulation .. 1,000+ known mutations .. 13,000+ diagnosed WW (51% female/49% male4) Fabry is a rare inherited genetic disorder caused by the deficiency of the GLA enzyme Leading Causes of Death Life-Limiting Symptoms TRANSIE

Slide 11: Global Fabry Market
11 Global Fabry Market .. Fabry Disease is believed to be significantly underdiagnosed – Newborn screening studies suggest Fabry could be one of the more prevalent human genetic diseases (~1:1,000 to ~1:4,000) .. In 2021, Galafold was the fastest growing medicine for Fabry disease and the greatest c

Slide 12: 2021 Galafold Success
12 2021 Galafold Success Building on Galafold’s Success and Leveraging Leadership Position to Drive Continued Growth Galafold is indicated for adults with a confirmed diagnosis of Fabry Disease and an amenable variant. The most common adverse reactions reported with Galafold (≥10%) were headache, na

Slide 13: Key Performance Indicators Lay the Groundwork for 2022
13 Key Performance Indicators Lay the Groundwork for 2022 .. Hybrid business model (virtual/in-person) surpassed pre-COVID physician interactions .. Achieved estimated 49%+ global share of treated amenable patients .. Multiple new markets opened in 2021 .. Global mix of switch (~55%) and previously

Slide 14: Galafold Growth Opportunity
14 Penetration of diagnosed untreated population Increase in newborn screening and diagnostic initiatives Strong intellectual property rights Continued penetration into existing markets Expansion into new geographies Broadening of labels Galafold Growth Opportunity $1B Annual Sales Opportunity at Pe

Slide 15: Global Commercial Infrastructure
15 - 43 countries with approvals - 35 countries reimbursed sales - Presence in 43 countries Experienced Global Commercial Team Global Commercial Infrastructure Highly Leverageable to Ensure Strong Global Launch of AT-GAA Galafold approvals in 40+ countries and commercial sales in 30+ of those today

Slide 16: AT-GAA (cipaglucosidase alfa + miglustat)
16 AT-GAA (cipaglucosidase alfa + miglustat) … potential to establish a new standard of care for people living with Pompe disease

Slide 17: Pompe Disease Overview
17 Deficiency of GAA leading to lysosomal glycogen accumulation and cellular dysfunction Age of onset ranges from infancy to adulthood Symptoms include muscle weakness, respiratory failure, and cardiomyopathy Respiratory and cardiac failure are leading causes of morbidity and mortality 5,000 – 10,00

Slide 18: Global Pompe Market
18 Global Pompe Market Global Pompe Disease Market Growth Continues to be Driven by the Diagnosis of New Patients, Only One Approved Therapy on the Market up until 2021 .. Pompe Disease believed to be significantly underdiagnosed – Newborn screening studies suggests Pompe to be more prevalent than m

Slide 19: AT-GAA: An Innovative Approach to Pompe Disease
19 AT-GAA: An Innovative Approach to Pompe Disease Our Scientists Created a Uniquely Glycosylated and Highly Phosphorylated ERT (ATB200) that Significantly Enhances Targeting to Key Affected Muscles .. AT-GAA is a two-component therapy combining ATB200, an ERT, with AT2221, an orally administered en

Slide 20: Clinically Meaningful Outcomes from Phase 3 PROPEL Study
20 Phase 3 PROPEL Study Clinically Meaningful Outcomes from Phase 3 PROPEL Study Provide the Basis for Global Regulatory Submissions of AT-GAA .. Peer-reviewed results from PROPEL suggest that treatment with AT-GAA provided clinically meaningful improvements over standard of care, including ERT-expe

Slide 21: PROPEL Study Results
21 Phase 3 PROPEL Study Results Endpoints Across Motor Function, Pulmonary Function, Muscle Strength, Pros, and Biomarkers Favored AT-GAA over Alglucosidase Alfa

Slide 22: AT-GAA: Key Takeaways
22 AT-GAA: Key Takeaways .. Regulatory status update: – U.S. PDUFA date mid 20221 – CHMP opinion late 2022 – Planning for additional regulatory submissions .. Multiple early access mechanisms in place, including U.K., Germany, Japan, and others .. 150+ people living with Pompe disease are on AT-GAA

Slide 23: Launch Preparations
23 Launch Preparations Experienced and Passionate Rare Disease Medical and Commercial Organization Poised for Second Successful Launch Key Strengths Commitment to patient access Clear focus on launch Identification of key Pompe disease centers Development of educational materials Planning Access Edu

Slide 24: Financial Summary
24 Financial Summary … maintaining a strong financial outlook

Slide 25: Transforming for the Future
25 Transforming for the Future We remain a global, patient-dedicated biotechnology company developing and delivering novel high-quality medicines for people living with rare diseases Focus will be to grow our leadership position across our two lead indications of Fabry disease and Pompe disease: – C

Slide 26: Financial Outlook and Path to Profitability
Financial Outlook and Path to Profitability Clear Strategy to Build our Business, Advance our Portfolio, and Achieve Profitability 1Preliminary and unaudited 26 Drive Revenue Growth Deliver on Financial Goals Secure Approvals of AT-GAA $306M1 full-year 2021 revenue 2022 Galafold revenue guidance of

Slide 27: Expanding Our Leadership Position in Fabry and Pompe
27 Expanding Our Leadership Position in Fabry and Pompe Differentiated Gene Therapy Approach for Greater Potency and Optimized Cross Correction through Transgene Engineering for Stability and Targeting Fabry Gene Therapy Pompe Gene Therapy .. Proprietary AAV capsid .. Pantropic capsid and ubiquitous

Slide 28: True Measure of Success: Impacting Patients' Lives
28 True Measure of Success: Impacting the Lives of Patients Living with Rare Diseases YE17 2023+ Thousands of Patients* >1,900+ Patients* YE21 >350 Patients* *Clinical & commercial, all figures approximate

Slide 29: Thank You
Thank You
Source: SEC EDGAR · 8-K filed Jan 10, 2022
More decks from Amicus Therapeutics Inc
Q3 2025 Earnings Presentation26 slides · Nov 4, 2025
Q2 2025 Earnings Presentation26 slides · Jul 31, 2025
Q1 2025 Earnings Presentation27 slides · May 1, 2025
FY2024 Earnings Presentation25 slides · Feb 19, 2025
43rd Annual J.P. Morgan Healthcare Conference (January 2025)35 slides · Jan 13, 2025
Q3 2024 Earnings Presentation23 slides · Nov 6, 2024